The earnings call presented a mixed picture with both positive and negative aspects. There were notable achievements in revenue growth and cost management, particularly in the pediatrics and heart failure segments, and improved reimbursement rates that could drive future growth. However, challenges remain with a significant decline in critical care sales and reduced gross margins, alongside issues in international sales. The sentiment leans towards a cautious optimism, with progress counterbalanced by current challenges.

Company Guidance -

Q2 2025

During the first quarter of 2025, Nuwellis reported $1.9 million in revenue, marking a 3% year-over-year increase, driven by a 4% rise in consumables utilization and increased U.S. console sales, despite a decrease in international sales. The company saw significant growth in the pediatrics and heart failure segments, with revenues increasing by 38% and 28% respectively, compared to the previous year. However, critical care sales declined by 25% due to a major customer acquiring excess inventory in late 2024. The gross margin fell to 56% from 64.1% a year earlier, primarily due to unfavorable manufacturing variances and inventory adjustments. Operating expenses decreased by 31%, from $4.6 million to $3.6 million, resulting in an operating loss of $3.1 million, an improvement from a $4.7 million loss in the first quarter of 2024. Net loss attributable to common shareholders was $3 million or $0.69 per share, compared to $3.8 million or $24.11 per share in the same period last year. Nuwellis ended the quarter with $2.6 million in cash and no debt, focusing on disciplined expense management and strategic growth initiatives, particularly in the pediatric and outpatient heart failure markets.

Revenue Growth

Nuwellis generated $1.9 million in revenue for Q1 2025, representing a 3% increase year-over-year, supported by a 4% increase in consumables utilization and an increase in U.S. console sales.

Strong Growth in Pediatrics and Heart Failure

Pediatrics and heart failure segments saw 38% and 28% growth over the prior year, respectively, driven by an increase in consumable utilization.

Reduction in Operating Expenses

Operating expenses reduced by 31% compared to Q1 2024, with selling, general and administrative expenses down by 22% and research and development expenses down by 57.7%.

Improved Reimbursement Coverage

Effective January 1, Aquadex was reassigned to a new outpatient reimbursed level by CMS, increasing the facility reimbursement fee by nearly 4x to $1,639 per day.

Reduction in Net Loss

Net loss attributable to common shareholders was reduced to $3 million or a loss of $0.69 per share compared to a net loss of $3.8 million or $24.11 per share in Q1 2024.

Nuwellis (NUWE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

NUWE Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 12, 2025	2025 (Q2)	-18.90 / -	-791.7	―	―	―
May 13, 2025	2025 (Q1)	-18.90 / -28.98	-882	96.71% (+853.02)	―
Mar 11, 2025	2024 (Q4)	-18.06 / -18.48	-3292.8	99.44% (+3274.32)	―
Nov 11, 2024	2024 (Q3)	-53.76 / 73.08	-2660.7	102.75% (+2733.78)	―
Aug 13, 2024	2024 (Q2)	-346.29 / -791.70	-5365.5	85.24% (+4573.80)	―
May 07, 2024	2024 (Q1)	-1558.20 / -882.00	-8467.2	89.58% (+7585.20)	―
Mar 05, 2024	2023 (Q4)	-2043.30 / -3292.80	-7350	55.20% (+4057.20)	―
Nov 07, 2023	2023 (Q3)	-4577.97 / -2660.70	-54390	95.11% (+51729.30)	―
Aug 08, 2023	2023 (Q2)	-5914.30 / -5365.50	-60270	91.10% (+54904.50)	―
May 09, 2023	2023 (Q1)	-5576.20 / -8467.20	-61740	86.29% (+53272.80)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

NUWE Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 13, 2025	$41.58	$41.96	+0.91%
Mar 11, 2025	$52.92	$50.82	-3.97%
Nov 11, 2024	$76.02	$86.10	+13.26%
Aug 13, 2024	$111.30	$89.88	-19.25%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Nuwellis (NUWE) report earnings?

Nuwellis (NUWE) is schdueled to report earning on Aug 12, 2025, TBA (Confirmed).

What is Nuwellis (NUWE) earnings time?

Nuwellis (NUWE) earnings time is at Aug 12, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is NUWE EPS forecast?

NUWE EPS forecast for the fiscal quarter 2025 (Q2) is -18.9.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing